Research programme: parathyroid hormone 1 receptor antagonists - Theratechnologies
Alternative Names: TH 1303; THG 1303; THG 1305Latest Information Update: 20 Mar 2008
Price :
$50 *
At a glance
- Originator Theratechnologies
- Class Peptides
- Mechanism of Action Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperparathyroidism; Malignant hypercalcaemia
Most Recent Events
- 14 Sep 2004 Data presented at the 86th Annual Meeting of the Endocrine Society (ENDO-2004) have been added to the Endocrine Disorders pharmacodynamics section
- 05 Jul 2004 Preclinical trials in Hyperparathyroidism in Canada (IV)
- 05 Jul 2004 Preclinical trials in Malignant hypercalcaemia in Canada (IV)